Synopsis: Pharma shares rose 10% upon signing an agreement with GMBU e.V., Halle (Saale), Germany, on 2 June 2026 for commercial-scale production of Astaxanthin at its Hyderabad R&D facilities. The pact follows successful pilot production and aims to scale...
Synopsis: Tata Group’s stock crashed about 35% in trade due to its 1:2 bonus issue. On the ex-date (4 June 2026), the stock price was adjusted downward mechanically, reflecting increased share count, not an actual loss in the company’s value. The shares of a...
Synopsis: Prism, OYO’s parent, has received SEBI approval for a ₹6,650 crore IPO. The fresh issue aims to fund expansion, strengthen finances, and improve operations. With strong institutional backing and governance upgrades, the company moves closer to its public...
Synopsis: Mamata Machinery shares rose 3% after securing an EU patent for its “Multi-Purpose Sealing Module,” strengthening its global IP base and supporting expansion into Europe, with India granted and US pending patents also in place. The shares of a micro-cap...
Synopsis: Aequs Ltd shares rose 4% after its subsidiary received Karnataka ESDM incentives for a Dharwad facility. The support lowers upfront costs, improves cash flow, and strengthens its manufacturing base, potentially boosting margins, speeding execution, and...
Synopsis: BEML has drawn attention after Elara Capital maintained a Buy rating with a ₹2,700 target, implying ~56% upside. A ₹159 billion order book ensures strong multi-year revenue visibility. Despite one-off profit pressure, the outlook stays positive, driven by...
Synopsis: Concord Biotech Ltd shares jumped 8% after USFDA approval for its ANDA of Mycophenolate Mofetil oral suspension (200 mg/mL). The drug is an immunosuppressant for transplant patients, including children. The approval enables entry into the ~$30 million US...
Synopsis: Natco Pharma has gained attention after Investec reiterated a Buy rating with a ₹1,220 target, implying 31% upside. The optimism is driven by strong core earnings, diversification beyond gRevlimid, semaglutide growth potential, global launches, a robust cash...
Synopsis: Dilip Buildcon’s ₹28,830 crore order book (4.3x market cap) signals strong revenue visibility, driven by diversified EPC projects across roads, mining, irrigation, and renewables. FY26 order inflows mark a sharp rebound after a prior decline. Growth...
Synopsis: FII and mutual fund activity showed notable institutional trading in select Indian stocks. Capri Global Capital and Lloyds Metals saw bulk deals with Morgan Stanley and BNP Paribas exchanging shares. RateGain Travel Technologies saw ICICI Prudential MF...
